Evidence review demonstrates beneficial effects of GLP-1 co-agonists on weight loss in cardiometabolic health, indicating improved patient outcomes.
Key Points
Incretin co-agonists significantly improve cardiometabolic health outcomes by reducing weight and glycated hemoglobin levels, enhancing metabolic profiles.
Dual GIP/GLP-1 receptor agonist tirzepatide shows lower gastrointestinal side effects while promoting weight loss and metabolic health benefits.
Many incretin co-agonists are designed for once-weekly administration, providing a more convenient therapeutic option for patients.
Promising pipeline agents, including novel dual and triple agonists, highlight potential for superior weight loss and cardiovascular outcomes in treatments.